You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Bifemelane hydrochloride
Bifemelane hydrochloride is an antidepressant MAO inhibitor. Reverses catalepsy induced by tetrabenazine in mice and increases locomotor activity in MPTP-treated marmosets.
Compound Libraries for Bifemelane hydrochloride
Technical Data for Bifemelane hydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Bifemelane hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Bifemelane hydrochloride
The following data is based on the product molecular weight 305.84. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.27 mL||16.35 mL||32.7 mL|
|5 mM||0.65 mL||3.27 mL||6.54 mL|
|10 mM||0.33 mL||1.63 mL||3.27 mL|
|50 mM||0.07 mL||0.33 mL||0.65 mL|
Product Datasheets for Bifemelane hydrochloride
References for Bifemelane hydrochloride
References are publications that support the biological activity of the product.
Naoi et al (1988) 4-(o-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(o-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J.Neurochem. 50 243 PMID: 3335842
Nomoto et al (1994) Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci.Lett. 178 95 PMID: 7816348
Tobe et al (1981) Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCl-2016), a new psychotropic drug with antidepressant activity. Arzneimittelforschung 31 1278 PMID: 7197535
If you know of a relevant reference for Bifemelane hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bifemelane hydrochloride, Bifemelane hydrochloride supplier, MAO-A, MAO-B, inhibitors, inhibits, Monoamine, oxygenases, Oxidases, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 0767, Tocris Bioscience
Citations for Bifemelane hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Bifemelane hydrochloride. Do you know of a great paper that uses Bifemelane hydrochloride from Tocris? Please let us know.
Reviews for Bifemelane hydrochloride
There are currently no reviews for this product. Be the first to review Bifemelane hydrochloride and earn rewards!
Have you used Bifemelane hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.